Home
Enviromental Illnesses
Study Video Highlight
EI Blog
Research and Support News
The Body Burden
EI Disease Biology
Environmental Factors
Mitigating Enviro Factors
Genetic /Biological Paths
Behavior Affecting EI
Behavioral Therapies
About Me
Shop
Home
Enviromental Illnesses
Study Video Highlight
EI Blog
Research and Support News
The Body Burden
EI Disease Biology
Environmental Factors
Mitigating Enviro Factors
Genetic /Biological Paths
Behavior Affecting EI
Behavioral Therapies
About Me
Shop
More
  • Home
  • Enviromental Illnesses
  • Study Video Highlight
  • EI Blog
  • Research and Support News
  • The Body Burden
  • EI Disease Biology
  • Environmental Factors
  • Mitigating Enviro Factors
  • Genetic /Biological Paths
  • Behavior Affecting EI
  • Behavioral Therapies
  • About Me
  • Shop
  • Home
  • Enviromental Illnesses
  • Study Video Highlight
  • EI Blog
  • Research and Support News
  • The Body Burden
  • EI Disease Biology
  • Environmental Factors
  • Mitigating Enviro Factors
  • Genetic /Biological Paths
  • Behavior Affecting EI
  • Behavioral Therapies
  • About Me
  • Shop

Video Playlist

Hello

Learn More About Orexin

www. eirn.org/f/orexins-and-vampire-syndrome-in-mecfs-and-long-covid

Itaconate Shunt

Itaconate Shunt- An Introduction

PHair and Davis have developed the itaconate shunt to explain what causes long-term consequences of MECFS. 

Itaconate Shunt and GABA Shunt

This is the second video in a series of 2 that explains why long-term health consequences occur in MECFS. 

Learn More About the Itaconate Shunt

The Itaconate Shunt by Phair and Davis

The Itaconate Shunt Hypothesis, proposed by Dr. Robert Phair in collaboration with Professor Ronald Davis at the Open Medicine Foundation, is a novel metabolic theory aimed at explaining the complex pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This hypothesis builds on earlier metabolomic findings and proposes that a dysregulation in the itaconate pathway—a key immune-metabolic route—may underlie many of the hallmark symptoms of ME/CFS, including post-exertional malaise, energy production deficits, and immune dysfunction. Itaconate is a metabolite produced by immune cells, particularly macrophages, in response to inflammation, and it plays a role in modulating both metabolism and immune responses. According to the hypothesis, in ME/CFS patients, a metabolic "shunt" diverts key intermediates from the tricarboxylic acid (TCA) cycle into the itaconate pathway, leading to a bottleneck in energy production. This diversion may be triggered or sustained by chronic immune activation or a failure to properly regulate inflammatory responses. The result is a buildup of metabolic intermediates and toxic byproducts like ammonia, which the body struggles to clear due to impaired nitrogen disposal mechanisms. This could explain why ME/CFS patients often rely on amino acids for energy—despite the inefficiency and toxicity of this route—because their cells are unable to effectively utilize glucose or fatty acids. The hypothesis also suggests that this metabolic trap could be self-sustaining, locking patients into a low-energy, high-inflammation state. Ongoing research, including modeling and experimental validation at the Open Medicine Foundation’s Melbourne Collaboration, is testing this hypothesis to determine whether targeting the itaconate pathway could offer therapeutic potential for ME/CFS  


Copyright © 2024 Environmental Illness Resource Network- All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept